2024年，健康元是如何回答“司生三大哲学问题”

Core Viewpoint - The article discusses the performance and transformation of the company, Health元, from a generic drug manufacturer to an innovative pharmaceutical enterprise, highlighting its financial results and strategic advancements in the respiratory drug market [2][3][10]. Financial Performance - As of April 7, 2024, Health元 reported a total revenue of 156.19 billion yuan and a net profit of 13.87 billion yuan for the fiscal year [2][4]. - The company has shown consistent growth, with total revenue exceeding 1,127.88 billion yuan and net profit surpassing 105.07 billion yuan from 2017 to 2024 [5][6]. - The revenue and net profit figures for the years 2017 to 2024 are as follows: - 2017: Revenue 107.79 billion yuan, Net Profit 21.33 billion yuan - 2018: Revenue 112 billion yuan, Net Profit 6.99 billion yuan - 2019: Revenue 119.8 billion yuan, Net Profit 8.94 billion yuan - 2020: Revenue 135.2 billion yuan, Net Profit 11.2 billion yuan - 2021: Revenue 159 billion yuan, Net Profit 13.28 billion yuan - 2022: Revenue 171.4 billion yuan, Net Profit 15.03 billion yuan - 2023: Revenue 166.5 billion yuan, Net Profit 14.43 billion yuan - 2024: Revenue 156.19 billion yuan, Net Profit 13.87 billion yuan [5][6]. Innovation and R&D - Health元 has transitioned to focus on innovative drugs, achieving significant breakthroughs in respiratory, analgesic, digestive, and psychiatric treatment areas [2][3]. - The company has developed 10 products in the respiratory field, with its first product,舒坦琳, achieving a 22-fold increase in sales over four years, establishing a leading position in the domestic respiratory market [2][3]. - Health元 has maintained a commitment to R&D, investing approximately 10% of its profits annually, with a total R&D expenditure of 15.32 billion yuan in 2024 [8][9]. Cash Flow and Shareholder Returns - The company has a strong cash flow, essential for sustaining operations in the high-investment pharmaceutical industry, and has maintained a stable cash flow while investing in R&D [6][7]. - Health元 has distributed a total of 39.79 billion yuan in dividends over 21 occasions since its listing in 2001, with a payout ratio of 89.37% [7][8]. - The company has executed share buybacks totaling nearly 40 billion yuan, enhancing shareholder value through share reduction and increased earnings per share [8][9].